Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.40
+1.4%
$1.31
$1.16
$9.15
$5.11M1.9524,821 shs23,652 shs
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
$5.33
-6.3%
$7.15
$3.82
$20.99
$5.07M1.28143,372 shs5,807 shs
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
$3.13
+1.3%
$6.90
$2.31
$223.60
$1.31M-0.321.83 million shs36,203 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.09
-0.9%
$1.49
$0.85
$6.92
$5.22M1.29133,829 shs47,663 shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
+1.45%+5.26%+10.24%-33.65%-83.17%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
-6.33%-4.82%-23.53%-45.50%-29.50%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
+1.29%-32.98%-43.09%-80.50%-97.71%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-0.91%-4.39%-5.22%-55.51%-66.97%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.40
+1.4%
$1.31
$1.16
$9.15
$5.11M1.9524,821 shs23,652 shs
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
$5.33
-6.3%
$7.15
$3.82
$20.99
$5.07M1.28143,372 shs5,807 shs
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
$3.13
+1.3%
$6.90
$2.31
$223.60
$1.31M-0.321.83 million shs36,203 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.09
-0.9%
$1.49
$0.85
$6.92
$5.22M1.29133,829 shs47,663 shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
+1.45%+5.26%+10.24%-33.65%-83.17%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
-6.33%-4.82%-23.53%-45.50%-29.50%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
+1.29%-32.98%-43.09%-80.50%-97.71%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-0.91%-4.39%-5.22%-55.51%-66.97%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
1.00
SellN/AN/A
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
1.00
SellN/AN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
2.00
HoldN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SLXN, SNOA, PULM, and RNAZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
DowngradeSell (D-)Sell (E+)
4/21/2026
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
Reiterated RatingSell (E+)
3/27/2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
Reiterated RatingSell (D-)
3/18/2026
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
Reiterated RatingSell (E+)
(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$7.81M0.65N/AN/A$2.45 per share0.57
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/A$11.27 per shareN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/AN/AN/AN/A$8.33 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$17.72M0.29N/AN/A$2.73 per share0.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$5.16M-$1.23N/AN/AN/AN/A-107.84%-91.58%8/12/2026 (Estimated)
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
-$34.66M-$50.33N/AN/AN/AN/A-875.35%-50.36%8/18/2026 (Estimated)
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-$11.91M-$80.50N/AN/AN/AN/A-516.86%-176.68%8/11/2026 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$2.04N/AN/AN/A-19.04%-42.56%-11.97%7/15/2026 (Estimated)

Latest SLXN, SNOA, PULM, and RNAZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2026Q1 2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A-$0.32N/A-$0.32N/AN/A
5/15/2026Q1 2026
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/A-$21.28N/A-$21.28N/AN/A
5/15/2026Q1 2026
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-$12.90-$0.85+$12.05$8.50N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/AN/AN/AN/AN/A
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/AN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A
4.96
4.96
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
3.11
3.11
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/A
1.00
1.00
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
2.88
2.00

Institutional Ownership

CompanyInstitutional Ownership
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
11.84%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
10.95%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.62%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
0.10%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
5.00%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
2.29%
CompanyEmployeesShares OutstandingFree FloatOptionable
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
203.65 million3.63 millionNot Optionable
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
9950,000949,000Not Optionable
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/A420,000398,000N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1804.79 million4.68 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals reports higher revenue
Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf

New MarketBeat Followers Over Time

Media Sentiment Over Time

Pulmatrix stock logo

Pulmatrix NASDAQ:PULM

$1.40 +0.02 (+1.45%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$1.40 0.00 (0.00%)
As of 06/12/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

TransCode Therapeutics stock logo

TransCode Therapeutics NASDAQ:RNAZ

$5.33 -0.36 (-6.33%)
Closing price 06/12/2026 03:51 PM Eastern
Extended Trading
$5.62 +0.29 (+5.42%)
As of 06/12/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Silexion Therapeutics stock logo

Silexion Therapeutics NASDAQ:SLXN

$3.13 +0.04 (+1.29%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$3.08 -0.05 (-1.73%)
As of 06/12/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$1.09 -0.01 (-0.91%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$1.07 -0.02 (-2.20%)
As of 06/12/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.